75美元的分水岭:Hyperliquid逼近关键决策点

ambcryptoPublished on 2026-07-03Last updated on 2026-07-03

Abstract

自2025年10月以来,比特币及大多数山寨币整体呈下跌趋势。然而,Hyperliquid [HYPE] 是少数长期趋势保持强劲看涨的大市值代币之一。其周线图显示看涨的波动结构已持续一年多,年内涨幅超74%。 近期HYPE在53.35美元至74.78美元区间内震荡。当前价格已突破64.1美元的中轴阻力及67.2美元的短期阻力,尽管有大户获利了结,但买盘需求吸收了抛压。在比特币看涨势头的带动下,HYPE有望继续上探75美元的关键供给区。 技术指标上,OBV稳步上升,RSI保持在50中性线上方,显示买压持续且看涨动能完好。但对于波段交易者而言,当前风险回报比并不理想。关键在于75美元区域的表现:若价格突破该阻力或从此处被拒绝并转跌,将为交易者提供明确的方向性交易信号。目前建议等待价格测试75美元区域后的市场反应,再行决策。

自2025年10月以来,比特币[BTC]和大多数山寨币一直处于下跌趋势。许多山寨币,即使是知名项目,也从未真正形成长期上涨趋势。过去几天BTC和其他代币的价格上涨,不过是下跌趋势中的一次反弹。

Hyperliquid [HYPE] 是少数维持坚定长期看涨趋势的大市值代币之一。

来源:TradingView 上的 HYPE/USDT

如上方的1周图所示,其波动结构已看涨超过一年。其交易价格为70.11美元,过去一周上涨7.51%,一年内涨幅超过74%

这巩固了长期看涨趋势,但近期相对强弱指数(RSI)正在形成较低的高点,而HYPE多头正试图将价格推至新高。因此,周线收盘价若突破72.1美元将呈现看跌背离,但这并不保证会立即回调。

以下是交易者和投资者可以预期的Hyperliquid代币价格走势。

HYPE 7月份价格预测

来源:TradingView 上的 HYPE/USDT

在过去一个月的交易中,该DEX代币形成了一个区间[紫色],范围在53.35美元至74.78美元之间。截至撰写本文时,价格已突破区间中部的阻力位64.1美元以及短期阻力区67.2美元

尽管有大户获利了结,价格依然向上推动。市场的需求吸收了这些卖盘。

结合比特币近期的看涨势头,HYPE很可能继续向75美元迈进。

能量潮指标(OBV)稳步攀升,RSI保持在50中性线上方。两者共同表明买盘压力稳定,看涨势头完好。

交易者行动指南 - 等待

来源:TradingView 上的 HYPE/USDT

需要突破该区间形态,才能开启下一个决定性的高时间框架走势。在此区间内,测试任一极端价位都可能为波段交易者提供入场机会。

但目前,这个机会尚未出现。截至撰写本文时,对于波段交易者而言,风险回报比并不理想。

技术指标偏向短期上行。因此,价格若向75美元供应区移动并在那里出现看跌反应,可用于卖出该代币,目标看向区间中部支撑位和区间底部支撑位。


最终总结

  • Hyperliquid是唯一维持长期看涨趋势的大市值加密资产之一。
  • 75美元的供应区对波段交易者至关重要。突破或从该区域被拒绝,都将是交易者进行方向性押注的信号。

Trending Cryptos

Related Questions

Q根据文章,Hyperliquid (HYPE) 的长期价格趋势如何?

A根据文章,Hyperliquid (HYPE) 的长期价格趋势是坚定看涨的。其波动结构已持续超过一年看涨,一年内涨幅超过74%,是少数维持长期看涨趋势的大市值加密资产之一。

Q在周线图上,什么情况预示着可能出现看跌背离?

A在周线图上,如果 HYPE 价格突破 72.1 美元,而相对强弱指数(RSI)却在形成近期更低的高点,那么这种价格创出新高但RSI未能跟上的情况,就预示着可能出现看跌背离。

Q文章指出,HYPE 在7月份的价格预测关键目标位是多少?为什么这个价位很重要?

A文章指出,HYPE 在7月份的价格预测关键目标位是75美元。这个价位很重要,因为它是一个关键的供应区域。无论是向上突破还是从此区域受阻回落,都将为交易者提供放置方向性押注的信号。

Q对于当前的 HYPE,文章给交易者的建议是什么(“行动呼吁”)?理由是什么?

A文章给交易者的建议是“等待”。理由是,虽然短期技术指标显示有上涨空间,但价格目前处于53.35美元至74.78美元的区间内。在区间被明确突破之前,当前的风险回报比对于波段交易者来说并不理想。

Q文章中提到了哪些技术指标来支持 HYPE 短期可能继续上涨的观点?

A文章中提到了两个技术指标来支持 HYPE 短期可能继续上涨的观点:1. 能量潮指标(OBV)正在稳步攀升,表明有持续的买入压力。2. 相对强弱指数(RSI)保持在50中性线上方,表明看涨势头依然完好。

Related Reads

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit28m ago

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit28m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit28m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit28m ago

Trading

Spot

Hot Articles

How to Buy SAND

Welcome to HTX.com! We've made purchasing The Sandbox (SAND) simple and convenient. Follow our step-by-step guide to embark on your crypto journey.Step 1: Create Your HTX AccountUse your email or phone number to sign up for a free account on HTX. Experience a hassle-free registration journey and unlock all features.Get My AccountStep 2: Go to Buy Crypto and Choose Your Payment MethodCredit/Debit Card: Use your Visa or Mastercard to buy The Sandbox (SAND) instantly.Balance: Use funds from your HTX account balance to trade seamlessly.Third Parties: We've added popular payment methods such as Google Pay and Apple Pay to enhance convenience.P2P: Trade directly with other users on HTX.Over-the-Counter (OTC): We offer tailor-made services and competitive exchange rates for traders.Step 3: Store Your The Sandbox (SAND)After purchasing your The Sandbox (SAND), store it in your HTX account. Alternatively, you can send it elsewhere via blockchain transfer or use it to trade other cryptocurrencies.Step 4: Trade The Sandbox (SAND)Easily trade The Sandbox (SAND) on HTX's spot market. Simply access your account, select your trading pair, execute your trades, and monitor in real-time. We offer a user-friendly experience for both beginners and seasoned traders.

5.5k Total ViewsPublished 2024.03.29Updated 2026.06.02

How to Buy SAND

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of SAND (SAND) are presented below.

活动图片